MedPath

Cemiplimab

Generic Name
Cemiplimab
Brand Names
Libtayo
Drug Type
Biotech
Chemical Formula
-
CAS Number
1801342-60-8
Unique Ingredient Identifier
6QVL057INT
Background

Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.

Cemiplimab was first approved by the FDA on September 28, 2018, as the first FDA-approved treatment for advanced cutaneous squamous cell carcinoma (CSCC). It was later approved to be used in basal cell carcinoma and non-small non-small cell lung cancer. Cemiplimab was also approved by the European Commission on June 28, 2019. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended cemiplimab be granted marketing authorization for the treatment of cervical cancer.

Indication

Cemiplimab is indicated to treat:

Associated Conditions
Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
Associated Therapies
First Line Chemotherapy
Clinical Trials
Related News
marketscreener.com
·

MAIA Biotechnology, Inc. Announces Expansion of Clinical Supply Agreement with ...

MAIA Biotechnology amended its 2021 clinical supply agreement with Regeneron to expand the THIO-101 trial, assessing THIO sequenced with Libtayo® for advanced NSCLC patients resistant to previous checkpoint inhibitors and chemotherapy. MAIA sponsors the trial, with Regeneron providing Libtayo® for all patients, including the expansion. MAIA holds an exclusive worldwide patent license for THIO and plans to enroll new patients soon, evaluating a potential accelerated approval in the U.S.
morningstar.com
·

MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron

MAIA Biotechnology expands 2021 clinical supply agreement with Regeneron for Phase 2 trial of THIO in non-small cell lung cancer, expecting new patient enrollment soon.

Related Clinical Trials:

THIO Sequenced with Cemiplimab in Advanced NSCLC
stocktitan.net
·

MAIA Biotech Expands Cancer Trial with Regeneron, Reports Promising NSCLC Results

MAIA Biotechnology expands 2021 clinical supply agreement with Regeneron for Phase 2 THIO-101 trial, evaluating THIO's efficacy with Libtayo® in third-line non-small cell lung cancer patients resistant to previous treatments. MAIA remains trial sponsor, with Regeneron supplying Libtayo®. Trial shows promising results in disease control, progression-free survival, and overall response rates. New patient enrollment planned, exploring potential accelerated approval in the U.S.

Related Clinical Trials:

THIO Sequenced with Cemiplimab in Advanced NSCLC
ir.maiabiotech.com
·

MAIA Biotechnology Expands 2021 Clinical Supply Agreement with Regeneron for Phase 2 THIO-101 Trial

MAIA Biotechnology expands its 2021 clinical supply agreement with Regeneron for the Phase 2 THIO-101 trial, focusing on THIO's efficacy in third-line non-small cell lung cancer patients. The trial assesses THIO followed by cemiplimab (Libtayo®) for patients resistant to previous treatments. MAIA anticipates new patient enrollment soon and explores accelerated approval opportunities in the U.S.

Related Clinical Trials:

THIO Sequenced with Cemiplimab in Advanced NSCLC
onclive.com
·

Osimertinib Is Most Impactful Addition to 2024 NSCLC NCCN Guidelines and Durvalumab

NCCN guidelines now recommend osimertinib for unresectable NSCLC with EGFR mutations and durvalumab for LS-SCLC, reflecting significant PFS and OS benefits from ADRIATIC and LAURA studies. These updates influence treatment discussions with patients, emphasizing upfront molecular testing and potential systemic therapy post-chemoradiation.

Related Clinical Trials:

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
finance.yahoo.com
·

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

Replimune submitted a BLA to the FDA for RP1, in combination with Bristol Myers' Opdivo, for advanced melanoma. The filing is under the FDA's Accelerated Approval pathway, supported by positive IGNYTE study results. The FDA also granted Breakthrough Therapy designation to RP1 for advanced melanoma, contributing to a 19.4% stock rise.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy